Agency Forms Undergoing Paperwork Reduction Act Review, 87582-87585 [2024-25552]
Download as PDF
<![CDATA[
87582
Federal Register / Vol. 89, No. 213 / Monday, November 4, 2024 / Notices
information to the U.S. NAC. These
forms will not only address the
biosafety and biosecurity containment
emergency elements of the GAP
standard but will also inform the U.S.
NAC risk assessments and thereby,
guide CDC’s determination of the
emergency response level and direction.
The information collected in the
Personal Protective Equipment (PPE)
Survey for Laboratories will assist the
CDC, U.S. NAC and NIOSH with
developing guidance and
recommendations for PPE selection and
use in support of poliovirus
containment as well as identify
laboratory PPE commonly used to
evaluate laboratory PPE performance
characteristics in testing studies.
Information collected in the GAP
Poliovirus Containment PoliovirusEssential Facility Assessment Checklist
will aid U.S. facilities in preparing for
an audit to obtain a poliovirus
certificate of containment. Data
collected from the GAP Poliovirus
Containment Poliovirus-Essential
Facility Questionnaire will collect
additional information on poliovirus
materials held by a U.S. facility, their
work activities, and facility features.
The Poliovirus Containment Sampling
Plan and Sanitation Assessment Form
for Wastewater (WW) Systems
Supporting a Poliovirus-Essential
Facility (PEF) in the United States will
collect information to assess poliovirus
essential facility’s wastewater system,
the primary safeguards to reduce and
control the release of poliovirus from
the facility. In addition, it will verify the
safeguards of local wastewater utilities
that receive wastewater from the PEF.
The Appeals and Complaints form is
a new form that will be made available
by the U.S. NAC of Poliovirus and will
allow facilities or persons to appeal or
forward complaints based on services
provided. This form can be used to
appeal or initiate complaints with
regards to specific survey outreach that
had been conducted or decisions
rendered by the audit team after an
audit.
OMB approval is sought for three
years. The annualized estimated time
burden for this information collection is
129 hours. There is no cost to
respondents other than their time.
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
responses per
respondent
Facility Incident Reporting Form for Poliovirus Release or Potential Exposure.
Facility Incident Reporting Form for Poliovirus Theft
or Loss.
Personal Protective Equipment Survey for Laboratories.
GAP Poliovirus Containment Poliovirus-Essential Facility Questionnaire.
GAP Facility Assessment Checklist ............................
The Poliovirus Containment Sampling Plan and Sanitation Assessment Form for Wastewater (WW)
Systems Supporting a Poliovirus-Essential Facility
(PEF) in the United States.
U.S. National Authority of Containment of Poliovirus
‘‘Appeals and Complaints Form’’.
10
1
45/60
8
10
1
45/60
8
20
1
1.5
30
20
1
1.5
30
20
20
1
1
1
1.5
20
30
10
1
15/60
3
......................................................................................
....................
........................
....................
129
Form name
Facility Staff/Leadership ....
Facility Staff/Leadership ....
Facility Staff/Leadership ....
Facility Staff/Leadership ....
Facility Staff/Leadership ....
Facility Staff/Leadership ....
Facility Staff/Leadership ....
Total ............................
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Public Health Ethics and
Regulations, Office of Science, Centers for
Disease Control and Prevention.
[FR Doc. 2024–25557 Filed 11–1–24; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
lotter on DSK11XQN23PROD with NOTICES1
[30Day-25–0666]
Agency Forms Undergoing Paperwork
Reduction Act Review
In accordance with the Paperwork
Reduction Act of 1995, the Centers for
Disease Control and Prevention (CDC)
has submitted the information
collection request titled ‘‘National
VerDate Sep<11>2014
Average
burden per
response
(in hours)
Number of
respondents
Type of respondents
17:28 Nov 01, 2024
Jkt 265001
Healthcare Safety Network’’ to the
Office of Management and Budget
(OMB) for review and approval. CDC
previously published a ‘‘Proposed Data
Collection Submitted for Public
Comment and Recommendations’’
notice on April 23, 2024 to obtain
comments from the public and affected
agencies. CDC received two comments
related to the previous notice. This
notice serves to allow an additional 30
days for public and affected agency
comments.
CDC will accept all comments for this
proposed information collection project.
The Office of Management and Budget
is particularly interested in comments
that:
(a) Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
Total
burden
(in hours)
(b) Evaluate the accuracy of the
agencies estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
(c) Enhance the quality, utility, and
clarity of the information to be
collected;
(d) Minimize the burden of the
collection of information on those who
are to respond, including, through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses; and
(e) Assess information collection
costs.
To request additional information on
the proposed project or to obtain a copy
of the information collection plan and
instruments, call (404) 639–7570.
Comments and recommendations for the
E:\FR\FM\04NON1.SGM
04NON1
87583
Federal Register / Vol. 89, No. 213 / Monday, November 4, 2024 / Notices
proposed information collection should
be sent within 30 days of publication of
this notice to www.reginfo.gov/public/
do/PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function. Direct written
comments and/or suggestions regarding
the items contained in this notice to the
Attention: CDC Desk Officer, Office of
Management and Budget, 725 17th
Street NW, Washington, DC 20503 or by
fax to (202) 395–5806. Provide written
comments within 30 days of notice
publication.
Proposed Project
National Healthcare Safety Network
(NHSN) (OMB Control No. 0920–0666,
Exp. 06/30/2026)—Revision—National
Center for Emerging and Zoonotic
Infectious Diseases (NCEZID), Centers
for Disease Control and Prevention
(CDC).
Background and Brief Description
The Division of Healthcare Quality
Promotion (DHQP), National Center for
Emerging and Zoonotic Infectious
Diseases (NCEZID), Centers for Disease
Control and Prevention (CDC) collects
data from healthcare facilities in the
National Healthcare Safety Network
(NHSN) under OMB Control Number
0920–0666. NHSN provides facilities,
health departments, states, regions, and
the nation with data necessary to
identify problem areas, measure the
progress of prevention efforts, and
ultimately eliminate healthcareassociated infections (HAIs) nationwide.
NHSN also allows healthcare facilities
to track blood safety errors and various
HAI prevention practice methods such
as healthcare personnel influenza
vaccine status and corresponding
infection control adherence rates.
The proposed changes in this new ICR
includes revisions made to 74 approved
NHSN data collection tools and 10 new
forms, for a total of 84 forms in this
package. CDC requests OMB approval
for an estimated 4,398,109 annual
burden hours. There is no cost to
respondents other than their time to
participate.
ESTIMATED ANNUALIZED BURDEN HOURS
1 ..........
2 ..........
3 ..........
4 ..........
5 ..........
6 ..........
7 ..........
8 ..........
9 ..........
10 ........
11 ........
12 ........
13 ........
14 ........
15 ........
16 ........
17
18
19
20
........
........
........
........
21 ........
lotter on DSK11XQN23PROD with NOTICES1
22 ........
23 ........
24 ........
25
26
27
28
........
........
........
........
57.100 NHSN Registration Form ...............................................................................
57.101 Facility Contact Information ...........................................................................
57.102 NHSN Help Desk Customer Satisfaction Survey ..........................................
57.103 Patient Safety Component—Annual Hospital Survey ....................................
57.104 NHSN Facility Administrator Change Request Form ....................................
57.105 Group Contact Information .............................................................................
57.106 Patient Safety Monthly Reporting Plan ..........................................................
57.108 Primary Bloodstream Infection (BSI) .............................................................
57.111 Pneumonia (PNEU) ........................................................................................
57.112 Ventilator-Associated Event (VAE) ................................................................
57.113 Pediatric Ventilator-Associated Event (PedVAE) ...........................................
57.114 Urinary Tract Infection (UTI) ..........................................................................
57.115 Custom Event .................................................................................................
57.116 Denominators for Neonatal Intensive Care Unit (NICU) ...............................
57.117 Denominators for Specialty Care Area (SCA)/Oncology (ONC) ...................
57.118 Denominators for Intensive Care Unit (ICU)/Other locations (not NICU or
SCA).
57.120 Surgical Site Infection (SSI) ...........................................................................
57.121 Denominator for Procedure ............................................................................
57.122 HAI Progress Report State Health Department Survey ................................
57.123 Antimicrobial Use and Resistance (AUR)—Microbiology Data Electronic
Upload Specification Tables—Initial Set-up.
57.123 Antimicrobial Use and Resistance (AUR)—Microbiology Data Electronic
Upload Specification Tables—Yearly Maintenance.
57.123 Antimicrobial Use and Resistance (AUR)—Microbiology Data Electronic
Upload Specification Tables—Monthly.
57.124 Antimicrobial Use and Resistance (AUR)—Pharmacy Data Electronic
Upload Specification Tables—Initial Set-up.
57.124 Antimicrobial Use and Resistance (AUR)—Pharmacy Data Electronic
Upload Specification Tables—Yearly Maintenance.
57.124 Antimicrobial Use and Resistance (AUR)—Pharmacy Data Electronic
Upload Specification Tables—Monthly.
57.125 Central Line Insertion Practices Adherence Monitoring ................................
57.126 MDRO or CDI Infection Form ........................................................................
57.127 MDRO and CDI Prevention Process and Outcome Measures Monthly
Monitoring.
57.128 Laboratory-identified MDRO or CDI Event ....................................................
57.129 Adult Sepsis ...................................................................................................
57.130 Pathogens of High Consequence ..................................................................
57.132 Patient Safety Component Digital Measure Reporting Plan (HOB, HT–CDI,
VTE, Adult Sepsis, RPS, NVAP)-IT Initial Set up.
57.132 Patient Safety Component Digital Measure Reporting Plan (HOB, HT–CDI,
VTE, Adult Sepsis, RPS, NVAP)-IT Yearly Maintenance.
57.132 Patient Safety Component Digital Measure Reporting Plan (HOB, HT–CDI,
VTE, Adult Sepsis, RPS, NVAP)-Infection Preventionist.
57.132 Patient Safety Digital Reporting Plan (RPS CSV) .........................................
VerDate Sep<11>2014
18:22 Nov 01, 2024
Jkt 265001
PO 00000
Frm 00047
Number of
responses per
respondent
Average
burden per
response
(min./hour 60)
2,000
2,000
26,400
5,400
800
1,000
7,821
6,000
1,800
5,463
334
6,000
600
1,100
500
5,500
1
1
1
1
1
1
12
12
2
8
1
12
91
12
12
60
5/60
10/60
2/60
137/60
5/60
5/60
15/60
42/60
34/60
32/60
34/60
24/60
39/60
240/60
300/60
300/60
3,800
3,800
55
2,200
12
12
1
1
14/60
14/60
50/60
4,800/60
3,300
2
120/60
5,500
12
5/60
1,500
1
2,400/60
4,000
1
120/60
5,500
12
5/60
500
720
5,500
213
12
29
26/60
34/60
15/60
4,800
50
3,650
5,500
12
12
365
1
24/60
28/60
30/60
1,620/60
5,500
1
1,200/60
5,500
4
10/60
5,500
365
2/60
Number of
respondents
Form number & name
Fmt 4703
Sfmt 4703
E:\FR\FM\04NON1.SGM
04NON1
87584
Federal Register / Vol. 89, No. 213 / Monday, November 4, 2024 / Notices
ESTIMATED ANNUALIZED BURDEN HOURS—Continued
29
30
31
32
........
........
........
........
33
34
35
36
37
38
39
40
........
........
........
........
........
........
........
........
41 ........
42 ........
43
44
45
46
47
48
49
50
51
........
........
........
........
........
........
........
........
........
52 ........
53 ........
54
55
56
57
58
........
........
........
........
........
59 ........
60 ........
61 ........
62 ........
63 ........
64 ........
65 ........
66 ........
lotter on DSK11XQN23PROD with NOTICES1
67
68
69
70
71
72
73
74
75
76
........
........
........
........
........
........
........
........
........
........
77 ........
57.133 Patient Safety Attestation ...............................................................................
57.137 Long-Term Care Facility Component—Annual Facility Survey .....................
57.138 Laboratory-identified MDRO or CDI Event for LTCF .....................................
57.139 MDRO and CDI Prevention Process Measures Monthly Monitoring for
LTCF.
57.140 Urinary Tract Infection (UTI) for LTCF ...........................................................
57.141 Monthly Reporting Plan for LTCF ..................................................................
57.142 Denominators for LTCF Locations .................................................................
57.143 Prevention Process Measures Monthly Monitoring for LTCF ........................
57.145 Long Term Care Antimicrobial Use (LTC–AU) Module CDA ........................
57.150 LTAC Annual Survey .....................................................................................
57.151 Rehab Annual Survey ....................................................................................
57.211 Weekly Healthcare Personnel Influenza Vaccination Cumulative Summary
for Non-Long-Term Care Facilities-Manual.
57.211 Weekly Healthcare Personnel Influenza Vaccination Cumulative Summary
for Non-Long-Term Care Facilities-.CSV.
57.214 Annual Healthcare Personnel Influenza Vaccination Summary-Manual .......
57.214 Annual Healthcare Personnel Influenza Vaccination Summary-.CSV ..........
57.215 Seasonal Survey on Influenza Vaccination Programs for Healthcare Personnel.
57.300 Hemovigilance Module Annual Survey ..........................................................
57.301 Hemovigilance Module Monthly Reporting Plan ............................................
57.302 Hemovigilance Module Monthly Incident Summary .......................................
57.303 Hemovigilance Module Monthly Reporting Denominators .............................
57.305 Hemovigilance Incident ..................................................................................
57.306 Hemovigilance Module Annual Survey—Non-acute care facility ..................
57.307 Hemovigilance Adverse Reaction—Acute Hemolytic Transfusion Reaction
57.308 Hemovigilance Adverse Reaction—Allergic Transfusion Reaction ...............
57.309 Hemovigilance Adverse Reaction—Delayed Hemolytic Transfusion Reaction.
57.310 Hemovigilance Adverse Reaction—Delayed Serologic Transfusion Reaction.
57.311 Hemovigilance Adverse Reaction—Febrile Non-hemolytic Transfusion Reaction.
57.312 Hemovigilance Adverse Reaction—Hypotensive Transfusion Reaction .......
57.313 Hemovigilance Adverse Reaction—Infection .................................................
57.314 Hemovigilance Adverse Reaction—Post Transfusion Purpura .....................
57.315 Hemovigilance Adverse Reaction—Transfusion Associated Dyspnea .........
57.316 Hemovigilance Adverse Reaction—Transfusion Associated Graft vs. Host
Disease.
57.317 Hemovigilance Adverse Reaction—Transfusion Related Acute Lung Injury
57.318 Hemovigilance Adverse Reaction—Transfusion Associated Circulatory
Overload.
57.319 Hemovigilance Adverse Reaction—Unknown Transfusion Reaction ............
57.320 Hemovigilance Adverse Reaction—Other Transfusion Reaction ..................
57.400 Outpatient Procedure Component—Annual Ambulatory Surgery Center
Survey.
57.401 Outpatient Procedure Component—Monthly Reporting Plan ........................
57.402 Outpatient Procedure Component Same Day Outcome Measures ..............
57.403 Outpatient Procedure Component—Denominators for Same Day Outcome
Measures.
57.404 Outpatient Procedure Component—SSI Denominator ..................................
57.405 Outpatient Procedure Component—Surgical Site (SSI) Event .....................
57.408 Monthly Survey Patient Days & Nurse Staffing .............................................
57.500 Outpatient Dialysis Center Practices Survey .................................................
57.501 Dialysis Monthly Reporting Plan ....................................................................
57.502 Dialysis Event .................................................................................................
57.503 Denominator for Outpatient Dialysis ..............................................................
57.504 Prevention Process Measures Monthly Monitoring for Dialysis ....................
57.507 Home Dialysis Center Practices Survey ........................................................
57.600 Neonatal Component FHIR Measure-Late Onset Sepsis Meningitis
(LOSMEN) Module-IT Initial Set up.
57.600 Neonatal Component FHIR Measure-Late Onset Sepsis Meningitis
(LOSMEN) Module-IT Yearly Maintenance.
57.600 Neonatal Component FHIR Measure-Late Onset Sepsis Meningitis
(LOSMEN) Module-Infection Preventionist.
57.600 Neonatal Component Late Onset Sepsis Meningitis (LOSMEN) Module
CDA Data Collection-Infection Preventionist.
57.601 Late Onset Sepsis/Meningitis Denominator Form: Late Onset Sepsis/Meningitis Denominator Form: Data Table for monthly electronic upload.
VerDate Sep<11>2014
18:22 Nov 01, 2024
Jkt 265001
PO 00000
Frm 00048
Number of
responses per
respondent
Average
burden per
response
(min./hour 60)
3,500
6,270
286
738
1
1
24
12
10/60
135/60
23/60
10/60
373
546
724
434
16,500
395
395
117
24
12
12
12
12
1
1
12
38/60
5/60
35/60
5/60
5/60
102/60
102/60
25/60
3,080
12
20/60
22,000
1,920
15,426
1
1
1
120/60
55/60
45/60
63
108
9
102
13
20
8
50
9
1
12
12
12
77
1
2
11
2
86/60
1/60
30/60
70/60
10/60
35/60
22/60
22/60
20/60
19
5
20/60
85
13
20/60
23
2
1
18
1
3
2
1
3
1
20/60
20/60
20/60
20/60
20/60
1
40
1
4
20/60
21/60
15
39
350
3
3
1
20/60
20/60
10/60
350
50
50
12
1
400
10/60
43/60
20/60
300
300
2,500
6,900
7,400
7,400
7,400
1,730
550
5,500
100
36
12
1
12
30
12
12
1
1
23/60
40/60
300/60
150/60
5/60
50/60
10/60
60/60
65/60
1,620/60
5,500
1
1,200/60
5,500
6
6/60
5,500
12
2/60
300
6
5/60
Number of
respondents
Form number & name
Fmt 4703
Sfmt 4703
E:\FR\FM\04NON1.SGM
04NON1
87585
Federal Register / Vol. 89, No. 213 / Monday, November 4, 2024 / Notices
ESTIMATED ANNUALIZED BURDEN HOURS—Continued
78 ........
79 ........
80
81
82
83
84
........
........
........
........
........
57.602 Late Onset Sepsis/Meningitis Event Form: Data Table for Monthly Electronic Upload.
57.700 Medication Safety-Digital Measure Reporting Plan (HYPO, HAKI, ORAE)—
IT Initial Set up.
57.700 Medication Safety-Digital Measure Reporting Plan (HYPO, HAKI, ORAE)—
IT Yearly Maintenance.
57.700 Medication Safety-Digital Measure Reporting Plan (HYPO, HAKI, ORAE)—
Infection Preventionist.
57.701 Glycemic Control Module-HYPO Annual Survey ...........................................
57.800 Billing Code Data: 837I Upload .....................................................................
57.801 External Validation Summary Report .............................................................
57.802 Bed Capacity-IT Initial Set Up .......................................................................
57.803 All Hazards .....................................................................................................
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Public Health Ethics and
Regulations, Office of Science, Centers for
Disease Control and Prevention.
[FR Doc. 2024–25552 Filed 11–1–24; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60-Day–25–25AU; Docket No. CDC–2024–
0088]
Proposed Data Collection Submitted
for Public Comment and
Recommendations
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice with comment period.
AGENCY:
The Centers for Disease
Control and Prevention (CDC), as part of
its continuing effort to reduce public
burden and maximize the utility of
government information, invites the
general public and other federal
agencies the opportunity to comment on
a proposed information collection, as
required by the Paperwork Reduction
Act of 1995. This notice invites
comment on a proposed information
collection project titled Risk factors,
clinical course, presence and
persistence of virus in various bodily
fluids, and risk of sexual transmission
among U.S. adults with Oropouche
virus (OROV) disease. This study will
assist in the response to this emerging
virus by; identifying risk factors for
infection to inform prevention guidance
and messaging, informing recognition,
diagnosis, follow-up care, and
counseling of patients with OROV
lotter on DSK11XQN23PROD with NOTICES1
SUMMARY:
VerDate Sep<11>2014
18:22 Nov 01, 2024
Jkt 265001
disease, and understanding risks of
sexual transmission to inform
prevention recommendations, especially
for pregnant people and their partners,
or those considering pregnancy.
DATES: CDC must receive written
comments on or before January 3, 2025.
ADDRESSES: You may submit comments,
identified by Docket No. CDC–2024–
0088 by either of the following methods:
• Federal eRulemaking Portal:
www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: Jeffrey M. Zirger, Information
Collection Review Office, Centers for
Disease Control and Prevention, 1600
Clifton Road NE, MS H21–8, Atlanta,
Georgia 30329.
Instructions: All submissions received
must include the agency name and
Docket Number. CDC will post, without
change, all relevant comments to
www.regulations.gov.
Please note: Submit all comments
through the Federal eRulemaking portal
(www.regulations.gov) or by U.S. mail to
the address listed above.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the information collection plan and
instruments, contact Jeffrey M. Zirger,
Information Collection Review Office,
Centers for Disease Control and
Prevention, 1600 Clifton Road NE, MS
H21–8, Atlanta, Georgia 30329;
Telephone: 404–639–7570; Email: omb@
cdc.gov.
SUPPLEMENTARY INFORMATION: Under the
Paperwork Reduction Act of 1995 (PRA)
(44 U.S.C. 3501–3520), federal agencies
must obtain approval from the Office of
Management and Budget (OMB) for each
collection of information they conduct
or sponsor. In addition, the PRA also
requires federal agencies to provide a
60-day notice in the Federal Register
concerning each proposed collection of
PO 00000
Frm 00049
Number of
responses per
respondent
Average
burden per
response
(min./hour 60)
300
6
6/60
5,500
1
1,620/60
5,500
1
1,200/60
5,500
4
10/60
10
5,500
20
25
540
1
4
2
1
365
180/60
5/60
15/60
20/60
5/60
Number of
respondents
Form number & name
Fmt 4703
Sfmt 4703
information, including each new
proposed collection, each proposed
extension of existing collection of
information, and each reinstatement of
previously approved information
collection before submitting the
collection to the OMB for approval. To
comply with this requirement, we are
publishing this notice of a proposed
data collection as described below.
The OMB is particularly interested in
comments that will help:
1. Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
2. Evaluate the accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
3. Enhance the quality, utility, and
clarity of the information to be
collected;
4. Minimize the burden of the
collection of information on those who
are to respond, including through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submissions
of responses; and
5. Assess information collection costs.
Proposed Project
Risk factors, clinical course, presence
and persistence of virus in various
bodily fluids, and risk of sexual
transmission among U.S. adults with
Oropouche virus (OROV) disease—
New—National Center for Emerging and
Zoonotic Infectious Diseases (NCEZID),
Centers for Disease Control and
Prevention (CDC).
E:\FR\FM\04NON1.SGM
04NON1
]]>Agencies
[Federal Register Volume 89, Number 213 (Monday, November 4, 2024)]
[Notices]
[Pages 87582-87585]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-25552]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[30Day-25-0666]
Agency Forms Undergoing Paperwork Reduction Act Review
In accordance with the Paperwork Reduction Act of 1995, the Centers
for Disease Control and Prevention (CDC) has submitted the information
collection request titled ``National Healthcare Safety Network'' to the
Office of Management and Budget (OMB) for review and approval. CDC
previously published a ``Proposed Data Collection Submitted for Public
Comment and Recommendations'' notice on April 23, 2024 to obtain
comments from the public and affected agencies. CDC received two
comments related to the previous notice. This notice serves to allow an
additional 30 days for public and affected agency comments.
CDC will accept all comments for this proposed information
collection project. The Office of Management and Budget is particularly
interested in comments that:
(a) Evaluate whether the proposed collection of information is
necessary for the proper performance of the functions of the agency,
including whether the information will have practical utility;
(b) Evaluate the accuracy of the agencies estimate of the burden of
the proposed collection of information, including the validity of the
methodology and assumptions used;
(c) Enhance the quality, utility, and clarity of the information to
be collected;
(d) Minimize the burden of the collection of information on those
who are to respond, including, through the use of appropriate
automated, electronic, mechanical, or other technological collection
techniques or other forms of information technology, e.g., permitting
electronic submission of responses; and
(e) Assess information collection costs.
To request additional information on the proposed project or to
obtain a copy of the information collection plan and instruments, call
(404) 639-7570. Comments and recommendations for the
[[Page 87583]]
proposed information collection should be sent within 30 days of
publication of this notice to www.reginfo.gov/public/do/PRAMain. Find
this particular information collection by selecting ``Currently under
30-day Review--Open for Public Comments'' or by using the search
function. Direct written comments and/or suggestions regarding the
items contained in this notice to the Attention: CDC Desk Officer,
Office of Management and Budget, 725 17th Street NW, Washington, DC
20503 or by fax to (202) 395-5806. Provide written comments within 30
days of notice publication.
Proposed Project
National Healthcare Safety Network (NHSN) (OMB Control No. 0920-
0666, Exp. 06/30/2026)--Revision--National Center for Emerging and
Zoonotic Infectious Diseases (NCEZID), Centers for Disease Control and
Prevention (CDC).
Background and Brief Description
The Division of Healthcare Quality Promotion (DHQP), National
Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Centers
for Disease Control and Prevention (CDC) collects data from healthcare
facilities in the National Healthcare Safety Network (NHSN) under OMB
Control Number 0920-0666. NHSN provides facilities, health departments,
states, regions, and the nation with data necessary to identify problem
areas, measure the progress of prevention efforts, and ultimately
eliminate healthcare-associated infections (HAIs) nationwide. NHSN also
allows healthcare facilities to track blood safety errors and various
HAI prevention practice methods such as healthcare personnel influenza
vaccine status and corresponding infection control adherence rates.
The proposed changes in this new ICR includes revisions made to 74
approved NHSN data collection tools and 10 new forms, for a total of 84
forms in this package. CDC requests OMB approval for an estimated
4,398,109 annual burden hours. There is no cost to respondents other
than their time to participate.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Number of Average burden
Form number & name Number of responses per per response
respondents respondent (min./hour 60)
----------------------------------------------------------------------------------------------------------------
1..................................... 57.100 NHSN Registration 2,000 1 5/60
Form.
2..................................... 57.101 Facility Contact 2,000 1 10/60
Information.
3..................................... 57.102 NHSN Help Desk 26,400 1 2/60
Customer Satisfaction
Survey.
4..................................... 57.103 Patient Safety 5,400 1 137/60
Component--Annual
Hospital Survey.
5..................................... 57.104 NHSN Facility 800 1 5/60
Administrator Change
Request Form.
6..................................... 57.105 Group Contact 1,000 1 5/60
Information.
7..................................... 57.106 Patient Safety 7,821 12 15/60
Monthly Reporting Plan.
8..................................... 57.108 Primary 6,000 12 42/60
Bloodstream Infection
(BSI).
9..................................... 57.111 Pneumonia (PNEU). 1,800 2 34/60
10.................................... 57.112 Ventilator- 5,463 8 32/60
Associated Event (VAE).
11.................................... 57.113 Pediatric 334 1 34/60
Ventilator-Associated
Event (PedVAE).
12.................................... 57.114 Urinary Tract 6,000 12 24/60
Infection (UTI).
13.................................... 57.115 Custom Event..... 600 91 39/60
14.................................... 57.116 Denominators for 1,100 12 240/60
Neonatal Intensive Care
Unit (NICU).
15.................................... 57.117 Denominators for 500 12 300/60
Specialty Care Area
(SCA)/Oncology (ONC).
16.................................... 57.118 Denominators for 5,500 60 300/60
Intensive Care Unit
(ICU)/Other locations
(not NICU or SCA).
17.................................... 57.120 Surgical Site 3,800 12 14/60
Infection (SSI).
18.................................... 57.121 Denominator for 3,800 12 14/60
Procedure.
19.................................... 57.122 HAI Progress 55 1 50/60
Report State Health
Department Survey.
20.................................... 57.123 Antimicrobial Use 2,200 1 4,800/60
and Resistance (AUR)--
Microbiology Data
Electronic Upload
Specification Tables--
Initial Set-up.
57.123 Antimicrobial Use 3,300 2 120/60
and Resistance (AUR)--
Microbiology Data
Electronic Upload
Specification Tables--
Yearly Maintenance.
57.123 Antimicrobial Use 5,500 12 5/60
and Resistance (AUR)--
Microbiology Data
Electronic Upload
Specification Tables--
Monthly.
21.................................... 57.124 Antimicrobial Use 1,500 1 2,400/60
and Resistance (AUR)--
Pharmacy Data
Electronic Upload
Specification Tables--
Initial Set-up.
57.124 Antimicrobial Use 4,000 1 120/60
and Resistance (AUR)--
Pharmacy Data
Electronic Upload
Specification Tables--
Yearly Maintenance.
57.124 Antimicrobial Use 5,500 12 5/60
and Resistance (AUR)--
Pharmacy Data
Electronic Upload
Specification Tables--
Monthly.
22.................................... 57.125 Central Line 500 213 26/60
Insertion Practices
Adherence Monitoring.
23.................................... 57.126 MDRO or CDI 720 12 34/60
Infection Form.
24.................................... 57.127 MDRO and CDI 5,500 29 15/60
Prevention Process and
Outcome Measures
Monthly Monitoring.
25.................................... 57.128 Laboratory- 4,800 12 24/60
identified MDRO or CDI
Event.
26.................................... 57.129 Adult Sepsis..... 50 12 28/60
27.................................... 57.130 Pathogens of High 3,650 365 30/60
Consequence.
28.................................... 57.132 Patient Safety 5,500 1 1,620/60
Component Digital
Measure Reporting Plan
(HOB, HT-CDI, VTE,
Adult Sepsis, RPS,
NVAP)-IT Initial Set up.
57.132 Patient Safety 5,500 1 1,200/60
Component Digital
Measure Reporting Plan
(HOB, HT-CDI, VTE,
Adult Sepsis, RPS,
NVAP)-IT Yearly
Maintenance.
57.132 Patient Safety 5,500 4 10/60
Component Digital
Measure Reporting Plan
(HOB, HT-CDI, VTE,
Adult Sepsis, RPS,
NVAP)-Infection
Preventionist.
57.132 Patient Safety 5,500 365 2/60
Digital Reporting Plan
(RPS CSV).
[[Page 87584]]
29.................................... 57.133 Patient Safety 3,500 1 10/60
Attestation.
30.................................... 57.137 Long-Term Care 6,270 1 135/60
Facility Component--
Annual Facility Survey.
31.................................... 57.138 Laboratory- 286 24 23/60
identified MDRO or CDI
Event for LTCF.
32.................................... 57.139 MDRO and CDI 738 12 10/60
Prevention Process
Measures Monthly
Monitoring for LTCF.
33.................................... 57.140 Urinary Tract 373 24 38/60
Infection (UTI) for
LTCF.
34.................................... 57.141 Monthly Reporting 546 12 5/60
Plan for LTCF.
35.................................... 57.142 Denominators for 724 12 35/60
LTCF Locations.
36.................................... 57.143 Prevention 434 12 5/60
Process Measures
Monthly Monitoring for
LTCF.
37.................................... 57.145 Long Term Care 16,500 12 5/60
Antimicrobial Use (LTC-
AU) Module CDA.
38.................................... 57.150 LTAC Annual 395 1 102/60
Survey.
39.................................... 57.151 Rehab Annual 395 1 102/60
Survey.
40.................................... 57.211 Weekly Healthcare 117 12 25/60
Personnel Influenza
Vaccination Cumulative
Summary for Non-Long-
Term Care Facilities-
Manual.
57.211 Weekly Healthcare 3,080 12 20/60
Personnel Influenza
Vaccination Cumulative
Summary for Non-Long-
Term Care Facilities-
.CSV.
41.................................... 57.214 Annual Healthcare 22,000 1 120/60
Personnel Influenza
Vaccination Summary-
Manual.
57.214 Annual Healthcare 1,920 1 55/60
Personnel Influenza
Vaccination Summary-
.CSV.
42.................................... 57.215 Seasonal Survey 15,426 1 45/60
on Influenza
Vaccination Programs
for Healthcare
Personnel.
43.................................... 57.300 Hemovigilance 63 1 86/60
Module Annual Survey.
44.................................... 57.301 Hemovigilance 108 12 1/60
Module Monthly
Reporting Plan.
45.................................... 57.302 Hemovigilance 9 12 30/60
Module Monthly Incident
Summary.
46.................................... 57.303 Hemovigilance 102 12 70/60
Module Monthly
Reporting Denominators.
47.................................... 57.305 Hemovigilance 13 77 10/60
Incident.
48.................................... 57.306 Hemovigilance 20 1 35/60
Module Annual Survey--
Non-acute care facility.
49.................................... 57.307 Hemovigilance 8 2 22/60
Adverse Reaction--Acute
Hemolytic Transfusion
Reaction.
50.................................... 57.308 Hemovigilance 50 11 22/60
Adverse Reaction--
Allergic Transfusion
Reaction.
51.................................... 57.309 Hemovigilance 9 2 20/60
Adverse Reaction--
Delayed Hemolytic
Transfusion Reaction.
52.................................... 57.310 Hemovigilance 19 5 20/60
Adverse Reaction--
Delayed Serologic
Transfusion Reaction.
53.................................... 57.311 Hemovigilance 85 13 20/60
Adverse Reaction--
Febrile Non-hemolytic
Transfusion Reaction.
54.................................... 57.312 Hemovigilance 23 3 20/60
Adverse Reaction--
Hypotensive Transfusion
Reaction.
55.................................... 57.313 Hemovigilance 2 2 20/60
Adverse Reaction--
Infection.
56.................................... 57.314 Hemovigilance 1 1 20/60
Adverse Reaction--Post
Transfusion Purpura.
57.................................... 57.315 Hemovigilance 18 3 20/60
Adverse Reaction--
Transfusion Associated
Dyspnea.
58.................................... 57.316 Hemovigilance 1 1 20/60
Adverse Reaction--
Transfusion Associated
Graft vs. Host Disease.
59.................................... 57.317 Hemovigilance 1 1 20/60
Adverse Reaction--
Transfusion Related
Acute Lung Injury.
60.................................... 57.318 Hemovigilance 40 4 21/60
Adverse Reaction--
Transfusion Associated
Circulatory Overload.
61.................................... 57.319 Hemovigilance 15 3 20/60
Adverse Reaction--
Unknown Transfusion
Reaction.
62.................................... 57.320 Hemovigilance 39 3 20/60
Adverse Reaction--Other
Transfusion Reaction.
63.................................... 57.400 Outpatient 350 1 10/60
Procedure Component--
Annual Ambulatory
Surgery Center Survey.
64.................................... 57.401 Outpatient 350 12 10/60
Procedure Component--
Monthly Reporting Plan.
65.................................... 57.402 Outpatient 50 1 43/60
Procedure Component
Same Day Outcome
Measures.
66.................................... 57.403 Outpatient 50 400 20/60
Procedure Component--
Denominators for Same
Day Outcome Measures.
67.................................... 57.404 Outpatient 300 100 23/60
Procedure Component--
SSI Denominator.
68.................................... 57.405 Outpatient 300 36 40/60
Procedure Component--
Surgical Site (SSI)
Event.
69.................................... 57.408 Monthly Survey 2,500 12 300/60
Patient Days & Nurse
Staffing.
70.................................... 57.500 Outpatient 6,900 1 150/60
Dialysis Center
Practices Survey.
71.................................... 57.501 Dialysis Monthly 7,400 12 5/60
Reporting Plan.
72.................................... 57.502 Dialysis Event... 7,400 30 50/60
73.................................... 57.503 Denominator for 7,400 12 10/60
Outpatient Dialysis.
74.................................... 57.504 Prevention 1,730 12 60/60
Process Measures
Monthly Monitoring for
Dialysis.
75.................................... 57.507 Home Dialysis 550 1 65/60
Center Practices Survey.
76.................................... 57.600 Neonatal 5,500 1 1,620/60
Component FHIR Measure-
Late Onset Sepsis
Meningitis (LOSMEN)
Module-IT Initial Set
up.
57.600 Neonatal 5,500 1 1,200/60
Component FHIR Measure-
Late Onset Sepsis
Meningitis (LOSMEN)
Module-IT Yearly
Maintenance.
57.600 Neonatal 5,500 6 6/60
Component FHIR Measure-
Late Onset Sepsis
Meningitis (LOSMEN)
Module-Infection
Preventionist.
57.600 Neonatal 5,500 12 2/60
Component Late Onset
Sepsis Meningitis
(LOSMEN) Module CDA
Data Collection-
Infection Preventionist.
77.................................... 57.601 Late Onset Sepsis/ 300 6 5/60
Meningitis Denominator
Form: Late Onset Sepsis/
Meningitis Denominator
Form: Data Table for
monthly electronic
upload.
[[Page 87585]]
78.................................... 57.602 Late Onset Sepsis/ 300 6 6/60
Meningitis Event Form:
Data Table for Monthly
Electronic Upload.
79.................................... 57.700 Medication Safety- 5,500 1 1,620/60
Digital Measure
Reporting Plan (HYPO,
HAKI, ORAE)--IT Initial
Set up.
57.700 Medication Safety- 5,500 1 1,200/60
Digital Measure
Reporting Plan (HYPO,
HAKI, ORAE)--IT Yearly
Maintenance.
57.700 Medication Safety- 5,500 4 10/60
Digital Measure
Reporting Plan (HYPO,
HAKI, ORAE)--Infection
Preventionist.
80.................................... 57.701 Glycemic Control 10 1 180/60
Module-HYPO Annual
Survey.
81.................................... 57.800 Billing Code 5,500 4 5/60
Data: 837I Upload.
82.................................... 57.801 External 20 2 15/60
Validation Summary
Report.
83.................................... 57.802 Bed Capacity-IT 25 1 20/60
Initial Set Up.
84.................................... 57.803 All Hazards...... 540 365 5/60
----------------------------------------------------------------------------------------------------------------
Jeffrey M. Zirger,
Lead, Information Collection Review Office, Office of Public Health
Ethics and Regulations, Office of Science, Centers for Disease Control
and Prevention.
[FR Doc. 2024-25552 Filed 11-1-24; 8:45 am]
BILLING CODE 4163-18-P
